<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418041</url>
  </required_header>
  <id_info>
    <org_study_id>2006-115</org_study_id>
    <nct_id>NCT00418041</nct_id>
  </id_info>
  <brief_title>Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)</brief_title>
  <official_title>Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroaki Shimokawa, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tohoku University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) is a&#xD;
      large, prospective, hospital-based cohort study to investigate the following:&#xD;
&#xD;
        -  Characteristics of patients with chronic heart failure and prognostic risks of these&#xD;
           patients.&#xD;
&#xD;
        -  Characteristics of patients with high risk for heart failure and critical factors which&#xD;
           predict the development of symptomatic heart failure in these patients.&#xD;
&#xD;
        -  The incidence and prognostic impact of metabolic syndrome in patients with chronic heart&#xD;
           failure.&#xD;
&#xD;
        -  The association between metabolic syndrome and the development of symptomatic heart&#xD;
           failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CHART-2 Study is a multicenter prospective observational cohort study identifying the&#xD;
      characteristics, mortality and prognostic risks of patients with overt HF and patients&#xD;
      without HF but who are at high risk for disease progression of cardiovascular diseases (CVD).&#xD;
&#xD;
      The purposes of the study are as follows:&#xD;
&#xD;
        1. to elucidate characteristics of patients with overt HF and the associated prognostic&#xD;
           risks&#xD;
&#xD;
        2. to elucidate characteristics of patients at risk for HF and the factors associated with&#xD;
           CVD progression&#xD;
&#xD;
        3. to elucidate factors associated with the development of AHFS&#xD;
&#xD;
        4. to elucidate prevalence and prognostic impact of metabolic syndrome (MetS) in patients&#xD;
           with overt HF&#xD;
&#xD;
        5. to elucidate the association between MetS and the development of AHFS&#xD;
&#xD;
        6. to elucidate the prevalence and prognostic impact of malignancy in patients with CVD&#xD;
&#xD;
        7. to elucidate the prevalence of patients needing home nursing care and the&#xD;
           characteristics of bedridden patients with CVD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause death</measure>
    <time_frame>At the time of registration and at least once a year thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-fatal acute myocardial infarction</measure>
    <time_frame>At the time of registration and at least once a year thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-fatal stroke</measure>
    <time_frame>At the time of registration and at least once a year thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure requiring admission</measure>
    <time_frame>At the time of registration and at least once a year thereafter</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Coronary Disease</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in teaching hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Structural heart disease but without signs or symptoms of heart failure.&#xD;
&#xD;
          -  Structural heart disease with prior or current symptoms of heart failure.&#xD;
&#xD;
          -  Refractory heart failure requiring specialized interventions.&#xD;
&#xD;
          -  Patients with prior cardiovascular surgery or percutaneous coronary intervention and&#xD;
             those who need such interventions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with age&lt;20 years old.&#xD;
&#xD;
          -  Patients who refused to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Shimokawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine</name>
      <address>
        <city>Sendai-city</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tohoku University</investigator_affiliation>
    <investigator_full_name>Hiroaki Shimokawa, MD, PhD</investigator_full_name>
    <investigator_title>Department of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

